The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Status:
Completed
Trial end date:
2020-09-09
Target enrollment:
Participant gender:
Summary
A small group of skin cancers of the head and neck, called resected cutaneous squamous
carcinomas, are more aggressive than most cancers of this type, even after being treated with
standard therapy. This trial will use stronger treatment to look at the safety and
effectiveness (efficacy) of combining a drug called Pembrolizumab with radiation after a
cancer has already been treated to suppress secondary tumor formation in high risk cutaneous
squamous cell cancer of the head and neck.
Primary Objective To assess safety by looking at the people with dose limiting responses